Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Evaluation will occur in four parts, with Part 1 being used to determine the appropriate doses of venetoclax and carfilzomib to use in later parts of the trial. Until appropriate doses have been confirmed, eligible participants will receive Venetoclax at a dose of 400 mg or 800 mg; Carfilzomib at a dose of 20/27 mg/m2, 20/70 mg/m2, and/or 20/56 mg/m2; and Dexamethasone at a 40 mg dose. Parts 2-4 will further evaluate the safety and efficacy of the treatment combination.